ImmuPharma plc (LON:IMM – Get Free Report)’s share price traded up 27.3% on Friday . The stock traded as high as GBX 5.70 ($0.07) and last traded at GBX 4.97 ($0.06). 13,061,318 shares were traded during mid-day trading, a decline of 40% from the average session volume of 21,589,580 shares. The stock had previously closed at GBX 3.90 ($0.05).
ImmuPharma Price Performance
The firm has a market cap of £20.51 million, a PE ratio of -492.40 and a beta of 1.53. The business has a 50-day moving average price of GBX 2.39 and a two-hundred day moving average price of GBX 1.93.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- Are Penny Stocks a Good Fit for Your Portfolio?
- Uber’s Business, Cash Flow, and AI are Why it Will Set a New High
- Business Services Stocks Investing
- Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
- Want to Profit on the Downtrend? Downtrends, Explained.
- These are the 3 Stocks Most Likely to Split in 2025
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
